News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories AI Agents News Research Digital Science Brings Real-World Research Impact Data Into AI Workflows With New Altmetric MCP Android eCommerce News Shopping Photoroom For Shopify Comes To Android, Completing Its Cross-Platform E-Commerce Workflow News Rocket Software Named a Challenger in the 2026 Gartner® Magic Quadrant™ for AI-Augmented Code Modernization Tools News Big Blue Bubble brings “Weird Al” Yankovic to the Musical World of My Singing Monsters News Earth Fire Alliance and Deepfire Collaborate to Support FireSat Data Delivery to Fire Agencies Worldwide News OtterlyAI backs The Ocean Cleanup